Puma Biotechnology Financials

PBYI Stock

USD 6.11 0.09 1.45%

Based on the key measurements obtained from Puma Biotechnology's financial statements, Puma Biotechnology may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. As of now, Puma Biotechnology's Property Plant And Equipment Net is increasing as compared to previous years. The Puma Biotechnology's current Non Currrent Assets Other is estimated to increase to about 4.3 M, while Total Assets are projected to decrease to under 168.9 M.

Cash Flow Balance Sheet Income Statement

Covid

Puma Biotechnology Balance Sheet Chart

As of now, Puma Biotechnology's Property Plant And Equipment Net is increasing as compared to previous years. The Puma Biotechnology's current Non Currrent Assets Other is estimated to increase to about 4.3 M, while Total Assets are projected to decrease to under 168.9 M.

Total Assets Cash Cash And Short Term Investments Common Stock Total Equity Common Stock Shares Outstanding

Add Fundamental

Key indicators impacting Puma Biotechnology's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

1.68

1.77

Notably Down

Slightly volatile

The essential information of the day-to-day investment outlook for Puma Biotechnology includes many different criteria found on its balance sheet. An individual investor should monitor Puma Biotechnology's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Puma Biotechnology.

Net Income

28.61 Million

Build AI portfolio with Puma Stock

Puma Biotechnology Stock Summary

Puma Biotechnology competes with Eledon Pharmaceuticals, Abeona Therapeutics, Voyager Therapeutics, Atea Pharmaceuticals, and Arcturus Therapeutics. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US74587V1070
Business Address	10880 Wilshire Boulevard,
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	www.pumabiotechnology.com
Phone	424 248 6500
Currency	USD - US Dollar

Puma Biotechnology Key Financial Ratios

	Return On Equity	0.4
	Profit Margin	0.17 %
	Operating Margin	0.18 %
	Price To Sales	1.47 X
	Revenue	230.47 M

More Fundamentals

Puma Biotechnology Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	226.6M	222.1M	230.5M	213.3M	245.3M	168.9M
Net Debt	53.5M	38.1M	26.9M	4.9M	5.6M	5.9M
Cash	63.1M	76.2M	84.6M	69.2M	79.6M	69.0M
Total Liab	229.0M	200.5M	177.1M	121.2M	139.4M	110.0M
Total Current Assets	140.0M	134.3M	156.2M	147.7M	169.8M	128.9M
Retained Earnings	(1.4B)	(1.4B)	(1.3B)	(1.3B)	(1.2B)	(1.1B)
Accounts Payable	11.2M	6.4M	6.9M	5.5M	6.3M	11.9M
Other Current Liab	94.8M	66.9M	53.7M	39.7M	45.7M	44.1M
Other Liab	9M	32.3M	6.4M	12.8M	14.7M	7.6M
Net Tangible Assets	(23.0M)	(80.1M)	(68.6M)	21.6M	19.4M	18.5M
Other Assets	5.1M	4.7M	4.7M	1.0	0.9	0.86
Long Term Debt	97.1M	98.3M	65.7M	21.7M	25.0M	23.7M
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	952.6M
Inventory	7.1M	4.5M	7.1M	8.7M	7.9M	8.1M
Other Current Assets	18.3M	6.4M	4.7M	6.0M	6.9M	9.5M
Intangible Assets	66.1M	70.6M	60.9M	51.1M	58.8M	35.8M
Net Receivables	32.5M	42.3M	48.5M	32.0M	36.8M	26.4M
Net Invested Capital	94.6M	119.9M	153.1M	159.2M	183.0M	140.2M
Net Working Capital	30.4M	56.8M	56.8M	51.5M	46.4M	48.7M

Puma Biotechnology Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	12.8M	11.6M	13.3M	12.5M	14.3M	15.0M
Operating Income	1.3M	23.7M	32.6M	31.0M	35.6M	37.4M
Ebit	(16.0M)	12.0M	36.0M	36.6M	42.0M	44.1M
Ebitda	(4.7M)	21.9M	47.5M	48.1M	55.3M	58.1M
Income Before Tax	(28.8M)	457K	22.7M	24.1M	21.7M	22.8M
Net Income	(29.1M)	2K	21.6M	30.3M	27.3M	28.6M
Total Revenue	253.2M	228.0M	235.6M	230.5M	265.0M	135.4M
Gross Profit	189.5M	172.9M	173.0M	166.1M	191.0M	106.8M
Research Development	71.9M	52.2M	50.4M	54.9M	49.4M	84.7M
Cost Of Revenue	63.7M	55.1M	62.7M	64.4M	74.1M	77.8M
Income Tax Expense	324K	455K	1.1M	(6.2M)	(5.6M)	(5.3M)
Net Interest Income	(12.6M)	(10.8M)	(10.9M)	(7.7M)	(7.0M)	(7.3M)
Interest Income	160K	813K	2.4M	4.7M	5.4M	5.7M
Tax Provision	324K	455K	841K	(6.2M)	(5.6M)	(5.3M)

Puma Biotechnology Key Cash Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Change In Cash	(22.2M)	3.5M	7.9M	(15.4M)	(13.8M)	(13.1M)
Free Cash Flow	20.7M	(22.8M)	14.4M	38.9M	44.7M	46.9M
Other Non Cash Items	7.1M	7.0M	1.5M	(519K)	(596.9K)	(567.0K)
Capital Expenditures	1K	7M	12.6M	56K	64.4K	61.2K
Net Income	(29.1M)	2K	21.6M	30.3M	27.3M	28.6M
End Period Cash Flow	75.3M	78.8M	86.7M	71.3M	82.0M	71.9M
Change To Inventory	(3.7M)	2.6M	(2.6M)	(1.6M)	(1.5M)	(1.6M)
Depreciation	11.3M	9.8M	11.5M	11.5M	13.3M	13.9M
Change To Netincome	66.6M	37.6M	39.8M	18.8M	21.7M	20.6M
Change Receivables	(8.1M)	2.4M	(6.0M)	(7.8M)	(7.0M)	(6.7M)
Investments	(10.9M)	14.1M	(22.8M)	(20.4M)	(23.5M)	(22.3M)

Puma Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Puma Biotechnology's current stock value. Our valuation model uses many indicators to compare Puma Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Puma Biotechnology competition to find correlations between indicators driving Puma Biotechnology's intrinsic value. More Info.

Puma Biotechnology is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about 0.25 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Puma Biotechnology is roughly 4.01 . As of now, Puma Biotechnology's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Puma Biotechnology's earnings, one of the primary drivers of an investment's value.

Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Enterprise Value Over EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Multiple is estimated to increase to 3.01, while Selling General Administrative is projected to decrease to under 67 M.

	2023	2024	2025	2026 (projected)
Reconciled Depreciation	10.2M	11.5M	13.3M	9.6M
Interest Income	2.4M	4.7M	5.4M	5.7M

Reconciled Depreciation Interest Income

Puma Biotechnology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Total Current Liabilities	Retained Earnings	Accounts Payable	Other Current Liab	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.2	0.2	0.5	0.57	-0.64	0.48	0.78	0.69	0.89	-0.64	0.75	-0.78	0.5	0.65	0.53	-0.13	0.53	0.66	0.36	0.32	-0.76	0.3	0.56	0.83	-0.02
Total Stockholder Equity	0.2		-0.75	0.38	0.31	-0.28	-0.26	-0.19	-0.58	0.56	-0.28	-0.34	0.33	0.18	-0.54	-0.36	0.9	-0.52	-0.52	0.36	0.47	0.32	0.57	-0.65	-0.2	0.13
Net Debt	0.2	-0.75		-0.56	-0.41	0.06	0.56	0.49	0.72	-0.16	0.06	0.61	-0.58	0.01	0.65	0.43	-0.8	0.57	0.7	-0.05	-0.25	-0.58	-0.02	0.69	0.5	-0.01
Cash	0.5	0.38	-0.56		0.92	-0.44	-0.05	0.27	0.14	0.59	-0.44	0.14	-0.25	0.24	0.13	0.17	0.21	0.06	0.09	-0.05	0.1	-0.24	-0.25	0.12	0.29	-0.22
Cash And Short Term Investments	0.57	0.31	-0.41	0.92		-0.51	0.11	0.39	0.25	0.6	-0.51	0.31	-0.36	0.23	0.26	0.26	0.08	0.23	0.22	-0.08	0.0	-0.35	-0.26	0.18	0.42	-0.28
Common Stock Total Equity	-0.64	-0.28	0.06	-0.44	-0.51		0.07	-0.43	-0.32	-0.63	1.0	-0.4	0.39	-0.36	-0.33	-0.23	0.02	-0.25	-0.32	-0.34	-0.22	0.39	-0.2	-0.22	-0.41	-0.1
Common Stock Shares Outstanding	0.48	-0.26	0.56	-0.05	0.11	0.07		0.72	0.6	0.17	0.07	0.77	-0.74	0.01	0.54	0.58	-0.46	0.39	0.74	-0.18	-0.3	-0.74	-0.13	0.41	0.8	-0.1
Other Stockholder Equity	0.78	-0.19	0.49	0.27	0.39	-0.43	0.72		0.79	0.49	-0.43	0.87	-0.96	0.34	0.77	0.65	-0.51	0.63	0.88	0.03	-0.16	-0.97	-0.07	0.6	0.95	-0.15
Total Liab	0.69	-0.58	0.72	0.14	0.25	-0.32	0.6	0.79		0.33	-0.32	0.88	-0.9	0.29	0.94	0.71	-0.78	0.82	0.93	0.03	-0.09	-0.88	-0.18	0.94	0.85	-0.12
Total Current Assets	0.89	0.56	-0.16	0.59	0.6	-0.63	0.17	0.49	0.33		-0.63	0.4	-0.44	0.53	0.29	0.21	0.28	0.22	0.25	0.51	0.53	-0.43	0.53	0.24	0.53	0.05
Common Stock	-0.64	-0.28	0.06	-0.44	-0.51	1.0	0.07	-0.43	-0.32	-0.63		-0.4	0.39	-0.36	-0.33	-0.23	0.02	-0.25	-0.32	-0.34	-0.22	0.39	-0.2	-0.22	-0.41	-0.1
Total Current Liabilities	0.75	-0.34	0.61	0.14	0.31	-0.4	0.77	0.87	0.88	0.4	-0.4		-0.92	0.19	0.89	0.78	-0.66	0.74	0.94	0.0	-0.18	-0.91	-0.12	0.68	0.93	0.0
Retained Earnings	-0.78	0.33	-0.58	-0.25	-0.36	0.39	-0.74	-0.96	-0.9	-0.44	0.39	-0.92		-0.36	-0.86	-0.69	0.61	-0.72	-0.94	-0.03	0.12	1.0	0.13	-0.75	-0.97	0.17
Accounts Payable	0.5	0.18	0.01	0.24	0.23	-0.36	0.01	0.34	0.29	0.53	-0.36	0.19	-0.36		0.16	0.02	0.03	0.22	0.19	0.75	0.7	-0.34	0.41	0.31	0.36	0.11
Other Current Liab	0.65	-0.54	0.65	0.13	0.26	-0.33	0.54	0.77	0.94	0.29	-0.33	0.89	-0.86	0.16		0.71	-0.75	0.89	0.92	-0.02	-0.15	-0.84	-0.22	0.85	0.8	-0.14
Other Liab	0.53	-0.36	0.43	0.17	0.26	-0.23	0.58	0.65	0.71	0.21	-0.23	0.78	-0.69	0.02	0.71		-0.58	0.67	0.8	-0.13	-0.23	-0.69	-0.27	0.57	0.69	-0.14
Net Tangible Assets	-0.13	0.9	-0.8	0.21	0.08	0.02	-0.46	-0.51	-0.78	0.28	0.02	-0.66	0.61	0.03	-0.75	-0.58		-0.65	-0.77	0.32	0.48	0.61	0.51	-0.74	-0.52	0.15
Property Plant And Equipment Net	0.53	-0.52	0.57	0.06	0.23	-0.25	0.39	0.63	0.82	0.22	-0.25	0.74	-0.72	0.22	0.89	0.67	-0.65		0.78	0.07	-0.03	-0.7	-0.16	0.76	0.65	-0.14
Non Current Assets Total	0.66	-0.52	0.7	0.09	0.22	-0.32	0.74	0.88	0.93	0.25	-0.32	0.94	-0.94	0.19	0.92	0.8	-0.77	0.78		-0.06	-0.23	-0.94	-0.25	0.8	0.92	-0.14
Non Currrent Assets Other	0.36	0.36	-0.05	-0.05	-0.08	-0.34	-0.18	0.03	0.03	0.51	-0.34	0.0	-0.03	0.75	-0.02	-0.13	0.32	0.07	-0.06		0.91	-0.02	0.74	0.06	0.05	0.54
Other Assets	0.32	0.47	-0.25	0.1	0.0	-0.22	-0.3	-0.16	-0.09	0.53	-0.22	-0.18	0.12	0.7	-0.15	-0.23	0.48	-0.03	-0.23	0.91		0.15	0.73	0.02	-0.07	0.31
Retained Earnings Total Equity	-0.76	0.32	-0.58	-0.24	-0.35	0.39	-0.74	-0.97	-0.88	-0.43	0.39	-0.91	1.0	-0.34	-0.84	-0.69	0.61	-0.7	-0.94	-0.02	0.15		0.13	-0.72	-0.97	0.17
Short Term Investments	0.3	0.57	-0.02	-0.25	-0.26	-0.2	-0.13	-0.07	-0.18	0.53	-0.2	-0.12	0.13	0.41	-0.22	-0.27	0.51	-0.16	-0.25	0.74	0.73	0.13		-0.19	-0.07	0.34
Non Current Liabilities Total	0.56	-0.65	0.69	0.12	0.18	-0.22	0.41	0.6	0.94	0.24	-0.22	0.68	-0.75	0.31	0.85	0.57	-0.74	0.76	0.8	0.06	0.02	-0.72	-0.19		0.68	-0.18
Capital Surpluse	0.83	-0.2	0.5	0.29	0.42	-0.41	0.8	0.95	0.85	0.53	-0.41	0.93	-0.97	0.36	0.8	0.69	-0.52	0.65	0.92	0.05	-0.07	-0.97	-0.07	0.68		-0.16
Inventory	-0.02	0.13	-0.01	-0.22	-0.28	-0.1	-0.1	-0.15	-0.12	0.05	-0.1	0.0	0.17	0.11	-0.14	-0.14	0.15	-0.14	-0.14	0.54	0.31	0.17	0.34	-0.18	-0.16

Click cells to compare fundamentals

Puma Biotechnology Account Relationship Matchups

Puma Biotechnology fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	226.6M	222.1M	230.5M	213.3M	245.3M	168.9M
Net Debt	53.5M	38.1M	26.9M	4.9M	5.6M	5.9M
Cash	63.1M	76.2M	84.6M	69.2M	79.6M	69.0M
Total Liab	229.0M	200.5M	177.1M	121.2M	139.4M	110.0M
Total Current Assets	140.0M	134.3M	156.2M	147.7M	169.8M	128.9M
Retained Earnings	(1.4B)	(1.4B)	(1.3B)	(1.3B)	(1.2B)	(1.1B)
Accounts Payable	11.2M	6.4M	6.9M	5.5M	6.3M	11.9M
Other Current Liab	94.8M	66.9M	53.7M	39.7M	45.7M	44.1M
Other Liab	9M	32.3M	6.4M	12.8M	14.7M	7.6M
Net Tangible Assets	(23.0M)	(80.1M)	(68.6M)	21.6M	19.4M	18.5M
Other Assets	5.1M	4.7M	4.7M	1.0	0.9	0.86
Long Term Debt	97.1M	98.3M	65.7M	21.7M	25.0M	23.7M
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	952.6M
Inventory	7.1M	4.5M	7.1M	8.7M	7.9M	8.1M
Other Current Assets	18.3M	6.4M	4.7M	6.0M	6.9M	9.5M
Intangible Assets	66.1M	70.6M	60.9M	51.1M	58.8M	35.8M
Net Receivables	32.5M	42.3M	48.5M	32.0M	36.8M	26.4M
Net Invested Capital	94.6M	119.9M	153.1M	159.2M	183.0M	140.2M
Net Working Capital	30.4M	56.8M	56.8M	51.5M	46.4M	48.7M

Puma Biotechnology Thematic Clasifications

Puma Biotechnology is part of several thematic ideas from Biotech to Cancer Fighters. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas

	Biotech		View
	Cancer Fighters		View

Today, most investors in Puma Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Puma Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Puma Biotechnology growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.17

As of now, Puma Biotechnology's Price Earnings To Growth Ratio is decreasing as compared to previous years.

Puma Biotechnology January 9, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Puma Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Puma Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Puma Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Puma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Puma Biotechnology's daily price indicators and compare them against related drivers.

	Downside Deviation	4.65
	Information Ratio	0.0732
	Maximum Drawdown	43.28
	Value At Risk	(3.85)
	Potential Upside	5.81

Complementary Tools for Puma Stock analysis

When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.

	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Puma Biotechnology Financials

Puma Biotechnology Balance Sheet Chart

Net Income

28.61 Million

Puma Biotechnology Stock Summary

Puma Biotechnology Key Financial Ratios

Puma Biotechnology Key Balance Sheet Accounts

Puma Biotechnology Key Income Statement Accounts

Puma Biotechnology Key Cash Accounts

Puma Financial Ratios Relationships

Puma Biotechnology fundamental ratios Correlations

Puma Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Puma Biotechnology fundamental ratios Accounts

Puma Biotechnology Thematic Clasifications

Price Earnings To Growth Ratio

0.17

Puma Biotechnology January 9, 2026 Opportunity Range

Complementary Tools for Puma Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Retained Earnings Total Equity	+ 1.0	Retained Earnings
Capital Surpluse	+ 0.95	Other Stockholder Equity
Other Current Liab	+ 0.94	Total Liab
Non Current Liabilities Total	+ 0.94	Total Liab
Non Current Assets Total	+ 0.94	Total Current Liabilities

Capital Surpluse	- 0.97	Retained Earnings Total Equity
Capital Surpluse	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.97	Other Stockholder Equity
Retained Earnings	- 0.96	Other Stockholder Equity
Retained Earnings Total Equity	- 0.94	Non Current Assets Total
Non Current Assets Total	- 0.94	Retained Earnings